How much is the influenza treatment market worth, and how is it expected to expand?
The influenza treatment market size has grown steadily in recent years. It will grow from $6.6 billion in 2024 to $6.9 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to a growth in number of annual influenza cases, increased government funding for influenza research and preparedness programs, public awareness campaigns promoting vaccination, the establishment of global influenza surveillance systems, and growth in healthcare facilities.
The influenza treatment market size is expected to see steady growth in the next few years. It will grow to $8.16 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to the introduction of new antiviral drugs and treatment modalities, expanding vaccination programs, continued expansion and improvement of healthcare infrastructure, increasing elderly population, and development of new treatments. Major trends in the forecast period include progress toward developing universal vaccines, innovations in vaccine delivery systems, integration of AI and big data, advances in personalized medicine, and increased collaborations between pharmaceutical companies.
Get Your Free Sample of The Global Influenza Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15832&type=smp
Which Market drivers have played a significant role in driving the influenza treatment market?
The increased prevalence of contagious respiratory illnesses is expected to propel the influenza treatment market going forward. Contagious respiratory illness refers to an infectious disease, such as influenza, measles, or respiratory syncytial virus (RSV) infections, transmitted through contact with an infected individual or their bodily fluids, contaminated surfaces, or objects. Factors driving the growth of contagious respiratory illness include higher population densities, inadequate healthcare infrastructure, misuse of antibiotics, and international travel facilitation. Influenza treatment consists of antiviral drugs and vaccinations that are used to treat various contagious respiratory illnesses such as flu, COVID-19, and other respiratory viruses. For instance, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the rate of hospitalizations linked to RSV (Respiratory Syncytial Virus) surged from 2 hospitalizations per 100,000 people during the week ending August 5, 2023, to 7 hospitalizations per 100,000 individuals by the week concluding on August 19, 2023. Therefore, the increased prevalence of contagious respiratory illnesses is driving the growth of the influenza treatment market.
What are the key segments within the influenza treatment market?
The influenza treatment market covered in this report is segmented –
1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
Subsegments:
1) By Peramivir: Intravenous Peramivir, Peramivir Injection
2) By Zanamivir: Inhaled Zanamivir, Zanamivir Diskhaler
3) By Oseltamivir Phosphate: Oseltamivir Capsules, Oseltamivir Oral Suspension
4) By Baloxavir Marboxil: Baloxavir Tablets, Baloxavir Granules For Oral Suspension
5) Other Products: Rimantadine, Amantadine
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report
Which key players are shaping the influenza treatment market?
Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.
Which transformative trends will shape the influenza treatment market landscape?
Major companies operating in the influenza treatment market are focusing on expanding their product portfolio by adding innovative solutions, such as single-dose oral medicine for influenza treatment, to enhance patient compliance, improve treatment outcomes, and capture a larger market share. A single-dose oral medicine refers to a medication designed to treat influenza (flu) with just one oral dose, simplifying the treatment regimen. For instance, in August 2022, Genentech Inc., a US-based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for Xofluza (Baloxavir Marboxil). Xofluza is the first and only single-dose oral medicine that offers a convenient and efficient solution for managing acute uncomplicated influenza in children aged five to less than 12 years who have been symptomatic for no more than 48 hours and other respiratory viruses.
How do regional factors impact the influenza treatment market, and which region is the largest contributor?
North America was the largest region in the influenza treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Influenza Treatment Market Report 2025 Offer?
The influenza treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Influenza treatment refers to medical interventions aimed at managing and alleviating symptoms, reducing the duration of illness, and preventing complications associated with influenza virus infections. Influenza treatments encompass antiviral medications and supportive care designed to mitigate flu symptoms, reduce disease duration, and prevent severe complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15832
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
